

Biomed/Biotech Interest Group – Special Event

“Worldwide Intellectual Property War and Its Impact on Pharmaceutical Industry in Taiwan and China – Asian Biomedical/Biotechnology Progress Update II”

Presented by

Keith Chan, PhD

(kchan@globoasia.com)

Professor, Graduate Institute of Intellectual Property
College of Commerce, National Chengchi University, Taiwan, ROC

Director of International Affairs

GloboAsia LLC and Revico Inc.

August 11, 2009 (Tuesday) Evening

6:00 PM – Networking and Pizza: and soft drink

6:30 – 7:00 PM – Program

7:00 – 8:00 PM – Q & A

Event is open to the public. Please consider \$4 chip-in for pizza & drink cost

Location:

Kelly's Deli Conference Center, 7519 Standish Place, Rockville, MD 20855

Driving directions:

From I-270 (N or S bound):

Take Exit 9A and exit from the first right exit.

Turn left (east) onto Shady Grove Dr.

Turn right (south) onto Rockville Pike (**Route 355**).

Turn left (east) onto East Gude Dr.

Turn left (north) immediately onto Crabb's Branch Dr.

Turn left (west) immediately onto Standish Place.

(The first building on your right side is 7519 Standish Place; open parking)

The conference room is on the first floor with its entrance opposite to the left side of building main entrance.

For headcount purpose, please register by Tuesday noon, August 11, 2009.

For registration: Please email Dr. George Chang,

at gchang2008@yahoo.com or call 240-793-8425.

A. Presentation Summary:

Worldwide Intellectual Property War and Its Impact on Pharmaceutical Industry in Taiwan and China

The 21st century has termed as the century of knowledge. However, knowledge is only a starting point. It is the protection of that knowledge and conversion of that knowledge into profit which are important for the survival of many high tech business and economy. The one who controls the knowledge and knows how to protect their core technology is the winner. In that sense, the biotech and pharmaceutical industry, like any other high-tech industry, is no different. The stakes are high, and the success or failure can make or break a company. Nowadays, the war of intellectual property is a worldwide affair. The impact

on Asia pharmaceutical is immense. This presentation will update you on the recent development in Taiwan and China.

B. Speakers' Bios:

Dr. Keith Chan obtained his PhD degree in Pharmaceutics from Univ. of Minnesota in 1980, and is currently **professor at the Graduate Institute of Intellectual Property, College of Commerce, National Chengchi Univ.** and adjunct Professor and Advisor at the Research Center for Drug Discovery, National Yang Ming Univ. in Taipei, Taiwan, ROC. He also serves as **Director of International Affairs, GloboAsia LLC and Revico Inc., Rockville, MD, USA** and as advisors for several research institutes and regulatory agencies in Asia, as well as consultants for several pharmaceutical firms in Asia and in the US. He is a co-founder of GloboMax LLC. He had served as adjunct Professor at the School of Pharmacy, University of Maryland at Baltimore and at the National Board of Advisor, College of Pharmacy, Univ. of Minnesota at Minneapolis since 1984. He worked for Ciba-Geigy Corporation in Ardsley, New York for 15 years and held various senior and management positions. He also worked for the US FDA as Division Director at the Office of Generic Drugs for 1.5 years. He was elected as fellow of the American Association of Pharmaceutical Scientists (AAPS) in 1995 for his scientific accomplishments on drug absorption in humans. He had organized numerous workshops and conferences in China, Taiwan, Hong Kong, Singapore, and Korea, serves as a scientific advisor for many regulatory agencies in Asia, and have successfully in assisted many Asian companies in their technology transfers and licensing deals to and from US as well as numerous regulatory submissions to the US FDA. His most recent accomplishment was to lead a Taiwan company to complete a new drug development program starting from IND up to human Phase II trial and then subsequently out-licensed it to a public US biopharmaceutical company.